和铂医药-B（02142）今日盘中大涨7.75%，引起市场广泛关注。该股价上涨主要得益于公司与阿斯利康达成重要战略合作，并获得后者的大额资金注入。
根据公告，和铂医药与阿斯利康Holdings达成战略合作，内容涵盖基于和铂医药专有的Harbour Mice全人源抗体技术平台在多治疗领域的多项目授权许可协议。作为回报，和铂医药将获得预付款、短期里程碑付款及额外项目的选项行使费用，总金额达1.75亿美元，以及最多44亿美元的额外开发和商业里程碑付款，还有净销售额的分级特许权使用费。这一合作不仅为和铂医药注入大量资金，更是对其创新抗体疗法研发能力的国际认可。
同时，双方还签署了股份认购协议。阿斯利康将以每股1.38美元（约10.74港元）的价格认购和铂医药76,271,762股新股，总融资额约1.053亿美元（约8.19亿港元）。这笔资金将用于研发投入、全球业务拓展及日常运营，支撑多特异性抗体管线的持续开发。这一战略合作和资金注入无疑增强了投资者对和铂医药未来发展前景的信心，推动了股价的上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.